AbbVie said full-year 2025 net revenues were $61.160 billion, up 8.6% on a reported basis (8.5% on an operational basis). Net revenues from its immunology portfolio were $30.406 billion, up 14.0%.

1. 01

   AbbVie said full-year 2025 net revenues were $61.160 billion, up 8.6% on a reported basis (8.5% on an operational basis). Net revenues from its immunology portfolio were $30.406 billion, up 14.0%.

2. 02

   The company said full-year 2025 diluted EPS was $2.36 on a GAAP basis, down 1.3%, and $10.00 on an adjusted basis, down 1.2%. It cited an unfavorable impact of $2.76 per share from acquired IPR&D and milestones expense in these results.

3. 03

   AbbVie said net revenues for Q4 2025 were $16.618 billion, up 10.0% on a reported basis. It said diluted EPS was $1.02 on a GAAP basis and $2.71 on an adjusted basis. The EPS includes an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense for Q4.

4. 04

   The company said it issued adjusted diluted EPS guidance for full-year 2026 of $14.37 to $14.57. It said the guidance excludes the impact of acquired IPR&D and milestones that may be incurred during 2026.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.